VAYEMAhttps://vayema.clinic/therapies/medications-opioid-use-disorder/

Medical treatment

Medications for Opioid Use Disorder: Options and FAQs

Understand methadone, buprenorphine and naltrexone for opioid use disorder, how treatment is selected, overdose prevention, ongoing care and common questions.

Clinically reviewed Dr. Sarah Boss, MD

Medications for opioid use disorder can reduce withdrawal, craving and the risk associated with returning to uncontrolled opioid use. The main options include methadone, buprenorphine and naltrexone. They work differently, and choosing between them requires an individual medical assessment.

Treatment is not simply about getting through withdrawal. It should help someone remain alive, regain stability and pursue the life they want. Medication can be a substantial part of recovery rather than a temporary obstacle to being considered recovered.

What is medication treatment for opioid use disorder?

The US Centers for Disease Control and Prevention recommends offering or arranging evidence-based medication treatment for opioid use disorder. It specifically cautions against detoxification alone because of the risks of returning to use and overdose.

Opioid use disorder can involve heroin, fentanyl or prescribed opioid medicines. Assessment considers the pattern of use and its consequences, not whether the substance originally came from a prescription.

The opioid-use disorder guide and prescription-opioid guide explain the wider treatment context. Physical dependence alone does not establish an addiction diagnosis, and each situation needs careful assessment.

Why maintenance treatment differs from detox

Maintenance treatment provides an ongoing prescribed medicine to support stability. Detoxification aims to manage withdrawal while stopping an opioid. These are different clinical strategies, not different levels of determination.

The NHS explanation of opioid treatment highlights the danger of reduced tolerance after detox. Returning to an amount previously used can cause an overdose because the body is no longer accustomed to it.

A decision about withdrawal should therefore include what happens afterward. A short admission without a continuing medication and support plan may leave important risks unresolved.

Methadone: reducing withdrawal and craving

SAMHSA describes methadone as a long-acting full opioid agonist. In an appropriately managed program, it can reduce withdrawal and craving and create a more stable alternative to repeated cycles of uncontrolled use.

Starting treatment and adjusting it require close clinical attention. Sedation, slowed breathing, interactions and some heart-rhythm risks are important considerations, particularly when other substances or medicines are involved.

Ask how dispensing, collection, monitoring and missed doses will be managed. These arrangements vary by jurisdiction and service; a description of a US opioid treatment program should not be assumed to describe every country’s system.

Buprenorphine: a partial opioid agonist

Buprenorphine activates opioid receptors differently from a full agonist. It can suppress withdrawal and craving, with a different safety profile from methadone. That does not mean it is risk-free, especially when combined with alcohol or other sedating substances.

Starting it at the wrong point can trigger sudden withdrawal. The appropriate initiation plan depends on the opioids being used, the person’s physical state and other clinical factors. A fixed online waiting period is not a safe substitute for assessment.

Some preparations combine buprenorphine with naloxone, and some services offer longer-acting formulations. Ask which product is being proposed and why its administration method suits your circumstances.

Naltrexone: blocking opioid effects

Naltrexone is an opioid antagonist: it blocks opioid receptors rather than providing an opioid effect. It is a different option for selected people who can safely complete the necessary opioid-free period before starting.

Beginning naltrexone while opioids remain in the body can cause severe withdrawal. Assessment also needs to consider liver health, planned pain treatment and the practical ability to continue the prescribed regimen.

Trying to overcome its blocking effect by taking more opioids is dangerous. Overdose risk also needs discussion when treatment wears off or stops, because tolerance may have fallen.

How the treatment choice is made

NICE recommends an individual choice between methadone and buprenorphine for opioid-dependence maintenance treatment, made with the clinician and patient. The discussion should consider previous response, risks, preferences and practical arrangements.

Tell the team about pain, mental health symptoms, other substance use, pregnancy and previous attempts at treatment. Difficult experiences with one medicine are relevant but do not automatically rule out all medication options.

Ask which goals the plan prioritizes and how it will adapt if circumstances change. A treatment that is theoretically suitable but impossible to access consistently may need a different delivery arrangement.

What does the evidence say about survival?

A cohort study of adults surviving an opioid overdose found that methadone and buprenorphine treatment were associated with lower subsequent mortality. As an observational study, it cannot answer every question about which medicine is best for an individual.

It does support the importance of engaging people in ongoing treatment after overdose rather than viewing discharge from emergency care as the end of the problem. The study could not draw a clear conclusion about naltrexone because exposure was limited.

Evidence should inform a practical plan: access to a prescriber, reliable follow-up and a way to return quickly after an interruption are as important as knowing a medicine’s name.

Starting treatment safely

Give an accurate account of what you have taken, including prescribed medicines, non-prescribed opioids and sedatives. Uncertainty about the contents of a substance is itself clinically relevant.

The team should explain how withdrawal, sedation and other symptoms will be assessed during initiation. Do not use another person’s prescription or reproduce a schedule found online.

Ask what to do if you miss appointments or doses. After an interruption, resuming a previous amount without advice may be unsafe. The service should make it clear how to obtain prompt review rather than leave you guessing.

Other medicines, pain and physical health

Alcohol, benzodiazepines and other sedating medicines can increase risk when combined with opioids. Disclose them so the clinical team can coordinate care; do not abruptly stop a prescribed sedative independently.

Ongoing pain still deserves assessment. Tell dentists, surgeons and emergency clinicians about opioid-use disorder treatment because it can affect pain-management choices, particularly when naltrexone is involved.

Chronic pain care and addiction treatment should be coordinated rather than treated as competing explanations. A person can need effective pain relief and support for opioid-related harm at the same time.

Naloxone and overdose prevention

Naloxone is an emergency overdose-reversal medicine, not the same treatment as naltrexone. Ask how to obtain an appropriate rescue kit and how trusted people can learn to recognize and respond to an overdose.

Its effects can wear off before those of the opioid. Emergency services are still needed, even when someone initially improves after an overdose-reversal medicine.

Keep prescribed treatment securely stored, especially around children. A medicine that is appropriate for its intended patient can be dangerous to someone else. Never share doses or leave them in an unlabeled container.

Psychological and practical support

Medication can create room to work on relationships, housing, trauma, routines and other concerns. Motivational interviewing and CBT-based relapse prevention offer different ways of supporting change.

The goals should be yours as well as the clinician’s. Returning to work, reducing conflict, sleeping more consistently or rebuilding trust may matter alongside changes in substance use.

Co-occurring mental health problems require attention rather than an assumption that everything will disappear once opioid use changes. The co-occurring conditions guide explains the value of coordinated care.

Duration, setbacks and stopping treatment

SAMHSA describes medication treatment as potentially lasting months or longer, including indefinitely when appropriate. There is no universal deadline after which continuing necessarily becomes a failure.

A return to use should trigger a review of risk and support needs, not a conclusion that the person is beyond help. Tell the team promptly so the treatment plan can be reassessed.

Reducing or stopping medication requires a shared plan that considers relapse and overdose risk. The withdrawal and deprescribing guide explains why the process needs to be individual rather than based on a standard online taper.

Frequently asked questions about opioid treatment medicines

Is this replacing one addiction with another?

Prescribed, monitored treatment aims to reduce harm and restore stability. Physical dependence on a medicine is not identical to compulsive, harmful use. Discuss the benefits and risks of the actual treatment rather than judging recovery by whether any medicine remains.

Is detox enough?

Withdrawal management alone does not resolve opioid use disorder. Ongoing treatment and overdose prevention are important, especially because tolerance falls after abstinence. Ask for the continuing plan before a detox course ends.

Are naloxone and naltrexone the same?

No. Naloxone is used to reverse an opioid overdose in an emergency. Naltrexone is a longer-acting treatment option used under a prescribing plan. Similar names should not lead to confusion about their purposes.

How long will I need medication?

The duration depends on benefit, risk and your circumstances. Some people continue long term. A review should consider functioning and safety rather than impose an arbitrary stopping date.

Can I receive treatment while pregnant?

Pregnancy requires coordinated specialist care, not an abrupt attempt to stop opioids alone. Tell the team promptly so maternal health, fetal well-being and the appropriate medicine and monitoring can be considered together.

What should I do after missing treatment?

Contact the prescribing service before restarting or compensating for missed doses. Tolerance and other risks may have changed. Seek urgent help for overdose symptoms or serious illness rather than waiting for a routine appointment.

Discussing your next step

A clinical assessment can help clarify opioid-related difficulties and an appropriate care pathway. Contact VAYEMA to discuss your current treatment and support needs.

Sources and further reading

  1. CDC: Treating opioid use disorder
  2. SAMHSA: Methadone
  3. SAMHSA: Buprenorphine
  4. SAMHSA: Naltrexone
  5. NICE: Methadone and buprenorphine
  6. Medication after overdose and mortality cohort study
  7. SAMHSA: Overdose-reversal medicines
  8. NHS: Opioid treatment and continuing support

Related conditions and concerns

These links explain the wider care context. They are not a recommendation that this approach is suitable for everyone with the condition. Use the condition treatment guide to understand alternatives and the role of clinical assessment.

Choosing the right support

Start with your needs, not a therapy label.

An assessment can help clarify what you are experiencing, compare appropriate options and establish whether a suitably trained professional is available. This guide does not confirm that VAYEMA offers the approach.

Discuss an assessment

This library is not an emergency service. If you cannot keep yourself or someone else safe, contact local emergency services or attend the nearest emergency department.

Start with a private assessment.

Private and discreet from the first conversation. Tell us how and when you prefer to be contacted, using contact details and practical preferences only.

VAYEMA

What would you like to explore?

Enter at least two characters to search.

VAYEMA

Private mental health care

Let us help you find the next step.

You do not need to choose a clinician or treatment program in advance.

Private and discreet from the first conversation. Tell us how and when you prefer to be contacted, using contact details and practical preferences only.

This form sends your information by email to [email protected]. Please do not include symptoms, medical histories, medication details or clinical documents.

Preferred session format

Select any that suit you.

Your preferred format, practitioner availability and any fees are discussed before an appointment is agreed. For urgent help, contact local emergency services rather than waiting for this form.

Prefer email? Contact [email protected].

Read our privacy information before sharing personal information.

VAYEMAYOUR NEXT STEP
Automated service guide Not clinical care English

You do not have to figure it out alone.

Explore what support could look like, at your own pace. You do not need a diagnosis or the right words to begin.